- Home
- GENI vs SUPN Comparison
GENI vs SUPN Comparison
Compare GENI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENI
- SUPN
- Stock Information
- Founded
- GENI 2016
- SUPN 2005
- Country
- GENI United Kingdom
- SUPN United States
- Employees
- GENI N/A
- SUPN N/A
- Industry
- GENI Services-Misc. Amusement & Recreation
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- GENI Consumer Discretionary
- SUPN Health Care
- Exchange
- GENI Nasdaq
- SUPN Nasdaq
- Market Cap
- GENI 3.0B
- SUPN 2.6B
- IPO Year
- GENI N/A
- SUPN 2012
- Fundamental
- Price
- GENI $12.48
- SUPN $45.71
- Analyst Decision
- GENI Strong Buy
- SUPN Buy
- Analyst Count
- GENI 16
- SUPN 2
- Target Price
- GENI $13.75
- SUPN $43.00
- AVG Volume (30 Days)
- GENI 4.9M
- SUPN 652.8K
- Earning Date
- GENI 08-06-2025
- SUPN 11-03-2025
- Dividend Yield
- GENI N/A
- SUPN N/A
- EPS Growth
- GENI N/A
- SUPN 1411.53
- EPS
- GENI N/A
- SUPN 1.14
- Revenue
- GENI $558,439,000.00
- SUPN $665,125,000.00
- Revenue This Year
- GENI $27.93
- SUPN $4.84
- Revenue Next Year
- GENI $16.92
- SUPN $17.69
- P/E Ratio
- GENI N/A
- SUPN $40.47
- Revenue Growth
- GENI 25.76
- SUPN 5.55
- 52 Week Low
- GENI $6.72
- SUPN $29.16
- 52 Week High
- GENI $13.73
- SUPN $46.79
- Technical
- Relative Strength Index (RSI)
- GENI 49.54
- SUPN 68.42
- Support Level
- GENI $12.31
- SUPN $45.26
- Resistance Level
- GENI $13.73
- SUPN $46.72
- Average True Range (ATR)
- GENI 0.41
- SUPN 1.02
- MACD
- GENI -0.13
- SUPN -0.21
- Stochastic Oscillator
- GENI 14.40
- SUPN 72.52
About GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.